Woodline Partners’s Immunogen Inc IMGN Stock Holding History

Woodline Partners’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-400,000	Closed	-$11.9M	–	674
2023 Q4	$11.9M	Sell	400,000 -2,033,161	-84%	-$40.5M	0.13%	209
2023 Q3	$38.6M	Sell	2,433,161 -114,478	-4%	-$1.9M	0.45%	49
2023 Q2	$48.1M	Buy	+2,547,639	New	+$30.1M	0.57%	44
2023 Q1	–	Sell	-5,027,027	Closed	-$24.9M	–	846
2022 Q4	$24.9M	Buy	+5,027,027	New	+$27.3M	0.33%	79
2022 Q1	–	Sell	-3,861,498	Closed	-$28.7M	–	856
2021 Q4	$28.7M	Buy	+3,861,498	New	+$24M	0.41%	53

Other funds holding IMGN

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Woodline Partners's IMGN Position: Q1 2024 in Review

Woodline Partners sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 400,000 shares — an estimated $11.9M sold.

Woodline Partners first reported a position in IMGN in Q4 2021 and held it in 5 quarters. The position peaked at $48.1M in Q2 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

Woodline Partners reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
Woodline Partners sold 400,000 Immunogen Inc shares in Q1 2024, an estimated $11.9M.
Woodline Partners first reported a position in Immunogen Inc in Q4 2021 and held it in 5 quarters.
Woodline Partners's Immunogen Inc position peaked at $48.1M in Q2 2023.
3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.